Ascendis Pharma A (ASND) Cash from Investing Activities (2014 - 2026)

Ascendis Pharma A has reported Cash from Investing Activities for 13 years, with the latest figure at -$7.9 million in Q1 2026.

• Quarterly Cash from Investing Activities fell 969.14% year-over-year to -$7.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$16.8 million (down 1532.97% YoY) and the FY2025 annual result came in at -$9.9 million, down 234.11% from the prior year.
• Cash from Investing Activities declined to -$7.9 million in Q1 2026 per ASND's latest filing, from -$3.9 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $226.1 million in Q1 2023 and troughed at -$7.9 million in Q1 2026.
• A 5-year average of $21.5 million and a median of $654747.6 in 2024 frame the typical range for Cash from Investing Activities.
• The sharpest annual moves came in 2023 and 2026: Cash from Investing Activities jumped 980.06% in 2023, then sank 969.14% in 2026.
• Over 5 years, Cash from Investing Activities stood at -$813137.2 in 2022, then jumped by 980.06% to $7.2 million in 2023, then sank by 105.5% to -$393243.1 in 2024, then plunged by 903.77% to -$3.9 million in 2025, then slumped by 100.29% to -$7.9 million in 2026.
• According to Business Quant data, Cash from Investing Activities over the past three periods registered -$7.9 million, -$3.9 million, and -$61959.9 for Q1 2026, Q4 2025, and Q3 2025 respectively.